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Double Heterozygotes for the Ashkenazi Founder
Mutations in BRCA1 and BRCA2 Genes
To the Editor:
Three Jewish founder mutations, 185delAG and
5382insC in BRCA1 and 6174delT in BRCA2 genes,
have been identified in breast cancer (BC) and ovarian
cancer (OC) Ashkenazi patients. In the Ashkenazi gen-
eral population, the carrier frequencies of these founder
mutations are 1% for 185delAG (Struewing et al. 1996),
0.13% for 5382insC, and 1.35% for 6174delT (Roa et
al. 1996; Oddoux et al. 1996). Given these high pop-
ulation frequencies, one would expect to find individuals
homozygous for the mutations 185delAG/185delAG,
6174delT/6174delT, and 5382insC/5382insC, com-
pound heterozygous for 185delAG/5382insC, or double
heterozygous for 185delAG/6174delT or 5382insC/
6174delT, provided the individuals are viable. The effect
of two mutations in a single individual is important both
for an understanding of the mode of action and inter-
action between the BRCA1 and BRCA2 genes and for
appropriate genetic counseling. To date, two double het-
erozygous patients (185delAG/6174delT; Ramus et al.
1997; Gershoni-Baruch et al. 1997) and one patient ho-
mozygous for a mutation in exon 11 of the BRCA1 gene
(Boyd et al. 1995) have been reported.
By pooling results from four cancer/genetics centers
in Israel, we have analyzed ∼1,500 BC/OC Ashkenazi
patients. All subjects received genetic counseling and
signed informed consent forms in compliance with in-
stitutional ethics committees (institutional review
boards). Each patient was tested for the three Ashkenazi
founder mutations: in BRCA1, the mutations 185delAG
and 5382insC, and in BRCA2, the mutation 6174delT
(Abeliovich et al. 1997; Levy-Lahad et al. 1997; Bruchim
Bar-Sade et al. 1998). Four patients were found to be
double heterozygotes. Summaries of their clinical status
and pedigrees are presented in table 1 and figure 1.
Patient 1 is an Ashkenazi mother of two children who
was diagnosed with unilateral breast cancer at the age
of 38 years. Her family history was positive for both
OC, with which her mother was diagnosed at the age
of 50 years, and breast cancer, with which her paternal
aunt was diagnosed at the age of 60 years and her daugh-
ter at the age of 35 years. Her paternal grandfather had
lung cancer at the age of 45 years. A test for 185delAG/
6174delT in her father revealed neither mutation; DNA
could not be retrieved from the paraffin block of her
mother. Analysis of the polymorphic markers D17S855,
D17S1322, D17S1323, D9S55, and D11S1337 in the
father and in Patient 1 confirmed paternity. It was thus
Table 1
Genotypes and Clinical Status of the Patients
Individual Genotype Clinical Status
Age at Diagnosis
(years)
Patient 1 185delAG/6174delT BC 38
Mother of Patient 1 185delAG/6174delTa OC 50
Patient 2 185delAG/6174delT OC 57
Patient 3 185delAG/6174delT Healthy 50
Patient 4 5382insC/6174delT BC 45
a Inferred genotype.
Figure 1 Pedigrees of Patients 1, 3, and 4. In parentheses is the inferred genotype and the ages at diagnosis.
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assumed that she had inherited both mutations from her
double heterozygous mother.
Patient 2 is a 57-year-old Ashkenazi woman who pre-
sented with stage IV OC. The patient is alive with no
evidence of disease 5 years after treatment. Her family
history includes breast cancer in her mother (age at di-
agnosis unknown). No further information was avail-
able. Patient 2 had irregular menses and primary sterility,
which were treated with low doses of steroids.
Patient 3 is a 50-year-old asymptomatic Ashkenazi
woman who was referred for evaluation of her breast
cancer risk before starting hormonal replacement ther-
apy for increasing loss in bone density. The maternal
family history was positive for ovarian, breast, pancreas,
stomach, and laryngeal cancers. Her father had prostate
cancer. The patient had idiopathic prematuremenopause
at the age of 37 years after bearing three children.
Patient 4 is a 46-year-old Ashkenazi woman who was
diagnosed with breast-infiltrating ductal carcinoma. The
family history was positive for cancer: hepatic carcinoma
at the age of 59 years in her mother and breast cancer
in her maternal grandmother. Two of her maternal cous-
ins and two more distant relatives had breast cancer at
the ages of 45, 48, and 42 years (the age at diagnosis
of one of the relatives is unknown). One of them is a
carrier of the mutation 5382insC. The others were not
available for mutation analysis.
As compared with carriers of single mutations, the
four double heterozygotes we observed did not have a
particularly severe phenotype, based on the tumor types
and age at diagnosis: one was unaffected at the age of
50 years; two were affected with unilateral breast cancer,
one at the age of 38 years and one at the age of 46 years;
and one was diagnosed with OC at the age of 57 years.
An inferred double heterozygote (the mother of Patient
1) had OC at the age of 50 years. None had more than
one primary tumor, and tumor histology and clinical
course were unremarkable. Two other 185delAG/
6174delT carriers were reported: one had BC and OC
diagnosed at the ages of 48 and 50 years, respectively
(Ramus et al. 1997); the other had bilateral BC at the
ages of 41 and 50 years, respectively (Gersoni-Baruch
et al. 1997).
Although the small number of cases precludes definite
conclusions, our results suggest that the phenotypic ef-
fects of double heterozygosity for BRCA1 and BRCA2
germ-line mutations are not cumulative. This is in agree-
ment with the observation that the phenotype of mice
that were homozygote knockouts for the BRCA1 and
BRCA2 genes was similar to that of mice that were
BRCA1 knockouts. This suggests that the BRCA1 mu-
tation is epistatic over the BRCA2 mutation (Ludwig et
al. 1997).
Interestingly, two of the double heterozygotes de-
scribed have had reproductive problems: one (Patient 2)
had primary sterility and irregular menses, and another
(Patient 3) had premature menopause at the age of 37
years. This latter patient was asymptomatic at the age
of 50 years. These preliminary observations raise the
possibility of hormonal effects in double heterozygotes,
including the possibility that the lack of estrogen may
have a protective effect.
At the population level, given the known heterozygote
frequencies in Ashkenazi Jews, the expected frequencies
of double heterozygotes would be the multiplication of
the heterozygote frequencies 185delAG/6174delT (1.35
# 104) and 5382insC/6174delT (1.75 # 105). The
expected frequencies of BRCA1 and BRCA2 homozy-
gotes will be the multiplication of the mutation fre-
quencies (approximately one-half of the heterozygote
frequency), which are 2.5 # 105 for 185delAG ho-
mozygotes and 4.6 # 105 for 6174delT homozygotes.
Therefore the ratio of 185delAG/6174delT double het-
erozygotes and 6174delT and 185delGA homozygotes
is 3:1:0.5, respectively. Namely, the double heterozy-
gotes should be about three to six times more common
than the homozygotes 185delAG or 6174delT. In this
respect, we might have expected to observe 185delAG
or 6174delT homozygotes. The fact that we did not
observe these or any other homozygotes may be due to
chance, and more patients should be tested before a ho-
mozygous patient is found or, alternatively, before ho-
mozygosity for 185delAG or 6174delT decreases via-
bility or causes different phenotypic consequences.
The clinical implication of this study is that mutation
analysis in Ashkenazi Jews should include all known
founder mutations. Identification of additional carriers
of more than one mutation will increase our understand-
ing of the interaction between various mutations and
will improve genetic counseling.
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Partial Triplication of mtDNA in Maternally
Transmitted Diabetes Mellitus and Deafness
To the Editor:
Maternally inherited diabetes and deafness (MIDD) is a
recently recognized subtype of diabetes mellitus (DM)
that is associated with mtDNA mutations (Maassen et
al. 1997). The first mtDNA defect described for MIDD
was a deletion associated with a duplication of the
mtDNA in a family presenting DM and deafness over
three generations (Ballinger et al. 1992, 1994). Subse-
quent to this observation, a mutation in nucleotide (nt)
3243 was reported in several pedigrees presenting DM
and deafness (Reardon et al. 1992; van den Ouweland
et al. 1992; Kadowaki et al. 1993). We report a partial
tandem triplication of 9.2 kb in one member of a family
presenting MIDD associated with a tandem duplication
of 4.6 kb.
In 1966, a 44-year-old man (II-7) of Italian origin was
hospitalized for insulin-dependent DM and hearing loss.
In 1973, his nephew (III-2), who was born in 1932, was
hospitalized for non–insulin-dependent DM and deaf-
ness. At that time, the morbid association led to a study
of the pedigree (fig. 1), which showed transmission of
DM and deafness over four generations, with a total of
13 affected individuals (Kressmann 1976). Seven indi-
viduals from the pedigree (III-3, III-4, IV-1, IV-2, IV-3,
IV-4, and IV-5) were examined by clinicians. The clinical
history was the same for all affected patients: the first
manifestation was deafness, beginning at 20–30 years
of age, with a rapid and severe increase in bilateral sen-
sory hearing loss. DM developed later in the 3d decade,
and insulin was required either immediately or at a later
date. At that time, the individuals from the fourth gen-
eration, who were !20 years of age, presented no deaf-
ness or DM. No pedigree member had ptosis, ophthal-
moplegia, or muscle weakness. Recently, the maternal
inheritance pattern of DM and deafness in this family
